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A B S TR A C T

Interleukin-10 Inhibits Cytokine-mediated Synergistic Release of
Interleukin-6 in Astrocytoma Cells
By
Liliya Vasileva Harizanova
Dr. Bryan L. Spangelo, Examination Com m ittee Chair
Professor of Chemistry
University of Nevada, Las Vegas
Astrocytes respond to pro-inflammatory cytokines such as, interleukin-1
(IL -IP ) and tumor necrosis factor (TN F-a). However, the m echanisms in which IL1(3 and T N F -a m ediate cell’s signaling need further investigation.
In previous research, the effects of y-aminobutyric acid (GABA) on IL-1
and T N F -a signaling pathway were studied. GABA was unable to suppress I kB-o
degradation and the phosphorylation of p38 by IL-1 (3 and T N F -a . However, it was
suggested that G ABA may be able to inhibit IL-6 release by reducing the rate of
I kB- o degradation.
Another cytokine, IL-10, which is well known in literature to have anti
inflammatory effects, is investigated in this study. This study presents IL-10
effects on the N F - k B and p38 signaling pathways as well as IL-10 inhibition of IL1 and T N F synergistic induction of IL-6 release. The effect of other signaling
molecules,

believed

to

act

as

antagonists

for p38

activation,

w ere

also

investigated and presented in this study. Previous studies indicate that both IL-1 (3

and

T N F -a

w ere

able

to

stimulate the

phosphorylation

of p38

and

the

degradation of N F - k B inhibitor, I kB- o , with no change in I k B-(3. W hile IL-10 is
unable to suppress the phosphorylation of p38 by IL-1 (3 or T N F -a or degradation
of I k B-o , inhibitor of N F - k B, it is also suggested that IL-10 m ay inhibit cytokinemediated synergistic induction of IL-6 in mechanistically similar w ay to GABA.
Inflammatory cytokines

IL-1 (3 and T N F -a

have

repeatedly shown to

phosphorylate p38 and activate N F - k B pathway. W e also have shown their
synergistic effect on release of extracellular IL-6 as well as synergistic increase in
transcriptional activation of IL-6 mRNA. Anti-inflammatory effects of IL-10, GABA
and p38 inhibitor S B 203580 w ere also investigated. Experim ental results suggest
that neither IL-10 nor G ABA can reverse p38 or N F - k B activation induced by ILip and T N F -a . However, they inhibit synergistic release of IL-6 but have no effect
on IL-6 transcriptional activation. Further, S B 203580, inhibitor of p38, decreased
synergistic m R N A transcript after stimulation with IL -ip and T N F -a . Our findings
may postulate that anti-inflammatory molecules such as G ABA and IL-10 may
have similar mode of action supposedly affecting post-translational mechanisms.
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C H A P TE R 1

IN TR O D U C T IO N
Biochemical Basis of the Central Nervous System
The biochemical basis of the central nervous system (C N S ) must be
discussed to better understand the nature of Alzheim er’s disease (A D ). The C N S
consists of two types of cells: glia and neurons. Neurons process and transmit
information

by

receiving

electrochemical

impulses

and

conducting

action

potentials and glia protect and support the neurons. Neurons are organized in
complex

networks to

perform

the function

of the

nervous

system.

O nce

stimulated, they transmit the action potentials to other neurons or effector organs
(Seely et. al 2000)
Neurons consist of a cell body also called soma and two types of
processes: dendrites and axons. The soma contains one nucleus which is
centrally located and contains extensive rough endoplasmic reticulum and Golgi
apparatus which indicates that this is the main site of protein synthesis. Dendrites
are cytoplasmic extensions that branch off the neuronal cell body and can be
stimulated to generate electric currents transmitted to the som a (S eely 200 0).
Axons are the extension of the neuronal soma. They have a constant diam eter
but can vary in length from few millimeters to more than one m eter. At their

terminal extensions axons form presynaptic terminais w here m any small vesicles
containing neurotransmitters are also present. Action potentials are conducted
along

the

axon

to

the

presynaptic

terminal,

w here

they

can

stimulate

neurotransmitter release.
Neuroglia, on the other hand, are far more numerous than the neurons.
They provide support,

protection and nutrition for neurons. They maintain

homeostasis, form myelin and participate in signal transduction in the nervous
system. Glial cells are divided into two subgroups according to their structure and
function;

macroglia

and

microglia.

Oligodendrocytes

and

astrocytes

are

macroglia. Oligodendrocytes have cytoplasmic extensions that surround and
wrap around the axons and produce the myelin sheet to protect the neuron,
except at the nodes of Ravier. Astrocytes possess extensions which spread out
to occupy areas close to the blood vessels and provide nutrients to the neurons
nearby. Astrocytes

regulate the extracellular composition of brain fluid by

releasing chemicals which promote the formation of tight junctions between
endothelial

cells

and

capillaries

(Seely

2000).

They

also

regulate

the

concentration of ions and gases and absorb and recycle neurotransmitters.
Microglia

provide the

immune defense for the

CNS

and

are

specialized

macrophages found around the brain and blood vessels. They becom e activated
in response to injury or inflammation and release cytokines and other signaling
molecules
substances.

to

repair

the

dam age,

phagocytize

microorganisms

or foreign

Neurotransmission
Since

glial cells lack an

excitable

m em brane, they cannot transfer

information. In order to transmit information in the C N S, neurons generate action
potentials that reach chemical or electrical synapses and finally post synaptic
receptor proteins. Presynaptic neurons receive signals causing them to release
either excitatory or inhibitory neurotransmitters.

These

signaling

molecules

eventually reach and bind receptors on a postsynaptic neuron, causing an action
potential to be generated. Subsequently, the postsynaptic neuron will propagate
either excitatory or inhibitory signal.
Neurotransmitter vesicles in the pre-synaptic neuron undergo exocytosis
in to the synaptic cleft in the w ake of an action potential. Once in the synapse,
the

neurotransmitter

can

then

bind

the

postsynaptic

receptors

on

the

postsynaptic neuron and continue the propagation of information in the neuronal
net.

Molecular Pathology of Alzheim er’s disease
A lzheim er’s disease (AD) affects many elderly people and is one of the
leading causes of death in developed nations. It is a slow but progressive
terminal disorder that is characterized by deterioration of cognitive and functional
abilities as well as psychiatric and behavioral symptoms (Yates et.al 2008). It
was first described by Alois Alzheim er in 1907 as a ‘peculiar disease of the
cortex’ that affects the C N S (Alzheimer, 1907). Nowadays, a century later, there
is still no cure for the disease and its cause is still unknown but there are various

hypotheses that have been developed

based on experim ental data (Behl,

C .,1999). Pathologists use three main biochemical features to define AD extracellular senile plaques, intracellular tau-rich (i-rich)

neurofibrillary tangles

(N FT) (G lenner and W ong, 1984) and inflammatory processes that contribute to
deposition and formation of senile plaques (Rogers et. Al, 1996).
Kang et al. reported in 1987 that amyloid plaques (AP) or develop from
amyloid

precursor protein (APP). A P P

is a ubiquitous Type

1 mem brane

glycoprotein and is generated throughout life in all mam m alian cells (Haass, C. et
al.,

1992). A P P

is processed

by P-secretase (BAC E)

containing y-secretase complex (Haas, 2004).

and

the presenilin-

p-secretase cleaves A P P to

produce a soluble version of A P P (P-APP) and a 99-residue CO O H-term inal
fragm ent that remains bound to the m em brane. This 99-rsidue fragment is a
substrate for y-secretase which performs the unusual cleavage in the middle of
the transm em brane domain to produce a 4-kD a Ap (Yoo-Hun Suh and Frederic
Checler, 2002). It is also worth noting that the A P P gene is located on the
chromosome 21, an extra copy of which characterizes Down Syndrome. Patients
suffering from both of these diseases exhibit increase amounts of Ap proteins
which leads to the formation of plaques (Mann and Esiri 1989). As suggested by
Wisniewski et al. (1985) overprexpression of A P P gene m ay accelerate the
developm ent of these neurodegenerative diseases although the cause is still not
understood.
It is generally believed that the abnormal processing of A P P leads to the
aggregation and deposition of Ap and ultimately leads to the pathogenesis of AD.

This understanding is generally referred to as ‘amyloid cascade hypothesis’ and
is supported by a large number of studies but is not entirely accepted (J. Hardy,
2006).
T he intracellular T-rich N F T ’s are another feature of AD . Like AP plaques,
N F T’s are formed by the aggregation of proteins that are on the inside of the
neuron and gradually fill the intracellular space. The main component of these
neurofibrillary tangles is microtubule-associated protein tau (C. Ballatore, 2007).
Under normal conditions tau is bound to the microtubules comprising the
neuronal skeleton and stabilizes their structure. In A D tau becomes detached
from the microtubules and aggregates to form N F T ’s. This process is also
associated with phosphorylation of tau proteins which m ay be the onset of NFT
formation.

Thus,

destabilized

neuronal

microtubules

and

N F T ’s

inclusions

seriously impair neuronal function even before cell death. Tau aggregates as
paired helical filaments (P H F ) to form the N F T ’s and in addition to that it is also
found around senile plaques (Duyckaerts C, Dickson D W ., 2003). There are
several kinases that are involved in tau phosphorylation and formation of P H F ’s
in AD, such as stress activated c-Jun N-terminal kinase (SAPK/JNK ) and p38
kinase (p38),

cyclin-dependent kinase-5 (CDK -5), glycogen synthase kinase-3p

(GSK-3P) ( Lovestone, Reynolds, 1997). Moreover, there two to three phosphate
groups per tau molecule in normal adult brain vs. hyperphosphorylation, which
results in 7-8 mol phosphates in AD (Ksiezak-Reding et al., 1992; Kopke et al.,
1993).

Inflammatory

responses

may

also

be

associated

with

AD

onset.

Documented occurrences of inflammatory processes in traum atic injuries to the
C N S and in chronic diseases such as AD, suggest that inflammatory cytokines
may be involved in neurodegenerative process (Schultzberg et al., 2007).
Cytokines are small, multifunctional proteins that respond to injuries and infection
and are produced by the glial cells when an inflammatory response is initiated.
Som e of the pro-inflammatory cytokines are interleukin-1 (IL-1), IL-6 and tumour
necrosis factor-a (T N F -a) and are involved in the initiation of the inflammatory
process. There are reciprocal interactions between proinflammatory cytokines
such as IL-1 (3 and IL-6, and APP/(3-amyloid (A(3) peptide (Buxbaum JD ,1992 and
Del Bo R, 1995). Cytokines stimulate the synthesis and metabolism of A PP and
A(3 peptide induces the production and secretion of cytokines (D el Bo R, 1995).
Depending on the A(3 peptide species and their aggregated forms the secretion
of cytokines from rat neonatal microglia proceeds via different mechanisms. For
instance, freshly dissolved A(3 peptides are more successful in initiating cytokine
release than other larger forms (Lindberg C., 2005). Increasing release of
proinflammatory cytokines regulates the processing and expression of A P P
which further leads to deposition of more A(3 fragm ents (G oldgaber D., 1989).
Microglial cells eventually becom e unsuccessful in removing these plaques and
lyse, releasing the collected fragments (N agele et al., 2004). This recursive
system continues leading to the expression of AD.

Mitogen-Activated Protein Kinases
Mitogen-Activated

Protein (M AP) kinases are serine/threonine-specific

protein kinases that respond to extracellular stimuli and regulate various cellular
activities. In m am m alian cells the M APK family consists of three main kinase
subfamilies, the c-Jun-N-term inal kinases (JNKs), the p38 kinases, and the
extracellular signal-regulated kinases (ERKs). The M A P K ’s phosphorylate on
specific serine and threonine residues of their target proteins. In addition, they
propagate and amplify external stimuli coming from the m em brane, going to the
cytoplasm

and

finally

reaching

the

nucleus

by

phosphorylating

and

dephosphorylating with the help of phosphatases. The c-Jun-N-term inal kinases
regulate gene transcription and are able to influence degenerative processes that
depend on de novo protein synthesis. The ERK subfamily is composed of ERK1
and ER K2 and they are primarily involved in cell division, differentiation and
proliferation.

The

p38

M AP

kinases are encoded

by four different genes

(p38a,p,y,5). They get activated in times of stress by inflammatory cytokines.
M A PK ’s are ubiquitously expressed and are present in nervous tissue. Growing
research suggests that p38 may be involved in neurodegenerative diseases such
as A D by contributing to neuronal death (Bendotti, C, 200 6). P38 is activated by
double phosphorylation of Thr 180 and Tyr 182 in a Thr-G ly-Tyr motif near the
active site in response to inflammatory stimuli such as T N F and IL-1 (3 (Ono, K.
and Han, J., 200 0). Interestingly, a substrate for p38 M A PK is tau protein. Once
phosphorylated, tau can accumulate to form N F T which is one of the hallmarks of
AD (Reynolds et al., 1997). P 38 contributes to the neurotoxicity of A(3.

Cytokines - Interleukin Family
Cytokines are low-molecular weight signaling proteins that are involved in
many

cell

processes

such

as

differentiation,

proliferation

and

cell death.

Cytokines can be divided according to their function. Som e can be classified as
growth factors,

pro- or anti-inflammatory

molecules

progression

immune

antigen.

of

response

to

an

or just aiding

Cytokines

are

in the

signaling

molecules such as the interleukin family (IL), tumor necrosis factor (TN F) and
many other growth factors. Cytokines can be classified in different families based
on structure and activity. The T N F family includes more than 20 different
members, encoded by different genes but with overlapping functions. The IL
family includes 33 members, identified by a number 1-33. Som e of the members
of IL-1 subfamily include cytokines IL-1|3 and IL-1 a which function as proinflammatory

molecules

(Dinarello,

C.A.,

2007).

The

IL-6

family

includes

members such as IL-6, leukemia inhibitory factor (LIF), and IL -1 1. The IL-10
family includes cytokines IL-10, IL-4 and IL-22 which are involved in inhibiting the
immune response (Dinarello, C.A. ,2007).
The IL-1 family of cytokines consists of three members: IL-1 a, IL-1 (3 and
their negative regulator (IL -Ira ). All three are encoded by a different gene but are
similar on a structural level. IL-1 a and (3 are agonist molecules because they
induce cellular responses. IL -Ira , however, binds to the sam e receptor but
inhibits the signaling of IL-1 and is therefore considered an antagonist (Dinarello
C A.

1994).

IL-1 a

and

|3 have similarities both

in gene

sequences and

structurally, being mainly composed of 12 to 14 folds of (3-pleated sheets (Murzin

A G, Lesk A M, Chothia C., 1992). In addition, the crystallographic structure of
these cytokines reveals an Arg residue at the sam e position that is necessary for
their biological function (Nanduri V B. et al., 1991). Inflammatory and stress
processes stimulate the transcription of IL-1 a and (3. In fact, Nawroth P. et al.
(1986) reported that T N F -a can stimulate the production of IL-1 in endothelial
cells. In addition, IL-1 or T N F -a were also found to induce release of IL-13 in vivo
(Dinarello G A.,

1989). The

IL -Ira

antagonist is primarily secreted in the

extracellular environment and is composed of 3-pleated sheets, similar to IL-1a
and 3 (Vigers G P. et al. 1994). Interestingly, IL -Ira has only one binding site for
its receptor, similar to IL-13, which was confirmed in a directed mutagenesis
study by Evans et al. in 1995. This fact also explains the interruption of signal
transmission in IL -I ra receptor antagonist.
Tum or necrosis factor-alpha (T N F -a) is a wide spread cytokine with
various functions,

such

as

promoting growth and

inhibition,

angiogenesis,

inflammation and cytotoxicity. Many cells have been reported to produce and
secrete T N F -a in response to infection or tumor growth. Immune cells are
primarily involved in the release of this cytokine (Aggarwal B B, Natarajan K.,
1996). T N F -a is initially synthesized as a 26 kDa m em brane-bound protein which
later is cleaved to a mature 17 kDa form while its prosequence part remains
associated with the m em brane (Jue D M., 1990). Being one of the main proinflammatory cytokines, T N F -a plays a central role in initiating and regulating
inflammatory processes. Bacterial lipopolysaccharide (LPS), injury, and viruses
can stimulate the expression of T N F (Vassalli P., 1992). Notably, T N F along with

interferon gam m a (IFN -y), potently stimulates other pro-inflammatory cytokines
such as IL-1 and IL-6 which in turn activate T and B cells and stimulate lepatic
acute phase protein synthesis. Interestingly, T N F is observed to be elevated in
the serum, C S F and cerebral cortex in AD patients (H. Fillit, W .H . Ding, L. Buee
et al., 1991). In 2001 Lucia et al. demonstrated that Ap induces production of
T N F in rat microglia. In addition, T N F as well as IL -ip w ere also found to exert
both neurotrophic or neurotoxic effects, depending on their concentration and site
of synthesis (Rothwell NJ, Hopkins SJ., 1995). This shows that T N F directly
contributes to A D through subsequent neuroinflammation.
Interleukin-6 is another pleiotropic cytokine that is involved in inflammation
processes in C N S. It is produced following viral or pathogen invasion as well as
during inflammation (Van Snick J.,

1990). The major species isolated from

human T-cell line w as reported to be an unglycosylated peptide with molecular
mass between 19 to 21 kD (Hirano et al., 1985). Moreover, Santham et al. (1989)
reported that

secreted IL-6 is glycosylated and its m olecular mass ranges from

23 to 30 kD. Previous studies show that IL-6 acts through gp130 receptor and
affects the functioning of B and T cells, neuronal cells and many others
(Kishimoto T, Akira S, Narazaki M, Taga T., 1995). It is interesting to note that IL6 has anti-inflammatory functions as well as a pro-inflammatory role. It induces
the production of IL -Ira , which is a receptor antagonist of IL-1
decreases

production

of T N F

(Tilg H,

Dinarello CA,

M ie rJ W .,

and also
1997).

By

decreasing the am ount of pro-inflammatory cytokines such as IL-1 and TN F, IL-6
actually

shows

an

anti-inflammatory

role.
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However,

it

is

found

in

high

concentrations in tissues under stress and is able to take part in inflammatory
processes. In addition, astrocytes and microglial cells in the C N S secrete IL-6 in
times of infection or increased concentrations of other inflammatory cytokines.
Moreover,

it has been

shown that IL-1P was able to activate the N F kB

transcription factor and thus stimulate IL-6 promoter transcriptional activity
(Zetterstrôm M. et al., 1998).

Signal Transduction Pathway of Interleukin - i p
The IL-1 family consists of at least three proteins - the agonist IL-1 a and P
and the receptor antagonist IL -Ira . IL-1 a and P are synthesized precursor
proteins. W hile IL-1 a is active in its precursor form, IL -ip needs further cleavage
by its converting enzym e (ICE; caspase-1), (Howard A D. et al., 1991). IL -Ira
exists in three forms - one secreted and known to block IL-1 activity, and two
additional intracellular forms which are all encoded by the sam e gene (Muzio M.
et al., 1995). There are two m em brane bound receptors - type I (IL-1R I) and type
II (IL-1R II). The signal is initiated upon binding of IL -ip to the type I receptor. The
IL -IR II is believed to be a non signaling receptor, serving as a decoy and trap for
IL-1 p. There is also an accessory protein involved in IL-1 signaling. The ILIR A c P accessory protein, exhibits structural similarities to IL-1R subtypes but is
unable to bind IL-1 alone. Instead, it forms a complex with IL-1RI and with any of
the IL-1 agonists (G reenfeder S A. et al., 1995). IL-1 binds to its receptor and its
accessory

protein

and

this trimeric complex

induces

binding

of myeloid-

differentiation primary binding protein to the formed complex. This allows the
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recruitment of IRAK -4 and IRAK-1. Phosphorylation of IRAK-1

results in the

binding of TR AP (TN F receptor associated factor)-6 to the initial complex. This
on the other hand, allows the dissociation of a part of the complex (TRA F6/phopho-IRAK-1) which binds to another m em brane bound protein complex
TAK-1. The phosphorylatioon of TAK-1 results in the degradation of
releasing the TR A F-6-TA K -1

IRAK-1,

from the protein complex associated with the

plasma m em brane (Akira, 2003). The fully activated TAK-1 protein activates
various signaling molecules that activate many genes through transcription
factors such as N F - k B. Interestingly, TAK-1 is also able to induce IL-1(3 mediated
activation of MARK signaling.

Nuclear Factor Transcription nuclear factor -

kB

kB

(N F - k B) belongs to the Rel family of

proteins. It is a dimeric protein with each chain containing an N-term inal 300
amino acids conserved region called the rel homology domain (R H D ). This
region is responsible for DMA binding and interaction with the N F - kB inhibitors,
I kB (Ghosh, 1998). In the cytoplasm, N F - k B is associated with its inhibitors I kB
preventing its migration to the nucleus for activated gene transcription. I kB is a
large family of inhibitors which include I kB- o , (3, e and y. The best studied and
characterized inhibitor is I kB- o , primarily due ti its initial discovery (Davis N.,
1991). In order to be activated, I kB- o needs to be phospshorylated on its Nterminal domain in response to chemical signals. I kB-(3 is less studied because it
was characterized after I kB- o . However, they both bind the sam e Rel subunits
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but respond differently to chemical signals. The difference in activity may be due
to strength or duration of signal. (Thompson J, 1995). Activated N F - kB promotes
the transcription of I k B-o for feedback supression. On the other hand, N F - kB,
once released from
Interestingly,

one

its inhibitor, does not promote transcription of I kB-|3.

can

correlate

this

perm anent

activation

of

N F - kB

to

inflammatory processes in A D which further exacerbate neurodegeneration.
According to Spiecker et al., (2000), I k B - e , which is much less studied
than the previously discussed inhibitors, and its functional relationship with NFkB

is not well understood. Finally, previous research suggests that k B -y inhibits

NF-kB by preventing it from binding to DNA by associating with different DNA
binding residues (Bell et al., 1996).
N F - k B is initially associated with its inhibitor IkB which in times of
inflammation is phosphorylated by I kB kinase (IKK), a type of transferase which
usually transfers

a

phosphate

group.

The

cell marks

the

phosphorylated

molecule for further degradation in the proteosome by ubiquitination. The other
product of the action of IKK is the released N F - kB which can translocate to the
nucleus and initiate transcription of various genes. These genes can encode
other pro-inflammatory cytokines such as IL-1, T N F and IL-6, which can further
stimulate the inflammatory process. Thus, the activation of N F - kB can be
assessed indirectly by measuring the degradation of its inhibitors.
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Y-Aminobutyric acid and catecholamines
y-Aminobutyric

acid

(GABA)

is

one

of

the

most

important

neurotransmitters in the C N S because it mediates m em brane hyperpolarization
and depolarization. It synthesis is accomplished by decarboxylation of glutamate
by glutamic acid decarboxylase (GAD). GABA is then further modified and
metabolized by the citric acid cycle. There are two classes of GABA receptors
which are divided according to their function: the ionotropic receptor GABA a and
the metabotropic receptor, G ABA b. GABA a receptors are chloride ion channels
which open following G ABA binding. GABA a receptors are primarily composed
of five different subunits each belonging to a different subclass (Sarto-Jackson I.,
2008). The G A B A b receptor is a metabotropic G protein coupled receptor which
initiates slow inhibitory responses. Activation of G A B A b receptors increases
potassium

conductivity

and

decreases

calcium

currents

which

may

be

responsible for the amelioration of neurotransmission (Kerr and Ong 2001).
Previous studies suggest that GABA can inhibit IL-1p m ediated IL-6 release
(Spangelo et al., 2004).
Other compounds that increase the intracellular level of cAM P also induce
IL-6 release. Catecholam ines are derived from tyrosine and contain catechol and
amine

groups.

The

catecholamines

include

epinephrine

(adrenaline),

norepinephrine (noradrenaline) and dopamine. Catecholam ines are hormones
secreted form the adrenal gland in response to not prolonged stress. Their mode
of action is through elevating cAM P intracellular levels. Other drugs which
elevate cA M P include cholera toxin and BuacAMP. In fact, previous results
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showed that BuacAMP increases IL-6 m RNA accumulation in and IL-6 release
from anterior pituitary cells (Spangelo et al., 1990). Interestingly, catecholamines
are also able to stimulate the synergistic release of IL-6 in the presence of
another cytokine, IL -ip (Zum walt et al., 1999). This is important in disease
processes in the C N S w here the level of cytokine production is elevated in
response to stress. Since AD is characterized by neurofibrillary tangles and
senile

plaques,

production

of IL-1

and

IL-6

m ay

further exacerbate

the

pathogenesis of this condition. Increasing levels of IL -ip m ay also increase
levels of catecholamines which can further increase production of IL-6 and
stimulate neuronal degradation.

Interleukin-10: An Anti-Inflammatory Cytokine
Astrocytes and microglial cells are activated in response to cellular injury
and brain traum a. Glia function in regulating the inflammatory reaction and
neuronal tissue repair in the C N S (Ridet et al.,

1997). Astrocytes secrete

cytokines and they also express m em brane cytokine receptors suggesting that
they can be targets of pro-inflammatory cytokines like IL -ip , T N F -a , or IL-6 (Ban
et al., 1993). IL-1 is well known to cause cell death of neurons and to induce
astrogliosis by the production of stress molecules such as nitric oxide (NO),
arachidonic acid derivatives, or cytokines (Lee et al., 1995). To counter this
process, the organism uses different tactics including the expression of IL -Ira
type II receptor ‘decoy’ and production of the anti-inflammatory cytokines IL-10
and IL-4. M oore et al., 1993 showed that IL-10 inhibits the production of the pro-
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inflammatory cytokines IL-1P, T N F -a and IL-6. Interleukin-10 was first described
by Fiorentino et al. in 1989 as a cytokine synthesis inhibitory factor (C SIF). First
described as an inhibitor of cytokine synthesis, it was classified as a Th-1immunosupressive cytokine similar to interferon gam m a and tumour necrosis
factor-alpha. C S IF was later cloned from human cD N A (Vieira et al., 1991) and
renamed IL-10. The human IL-10 gene encodes a protein of 178 amino acids
which is cleaved to produce a mature sequence of about 18kDa, containing four
cysteine residues (Windsor et al., 1993). It is noteworthy to mention that IL-4 is
another anti-inflammatory cytokine with similarities to IL-10. For instance, IL-10 is
synthesized in the normal brain (Wong et al., 1996) and in times of inflammation
and brain injury both cytokines are expressed (W oodroofe et al., 1993). Glial
cells were proposed to be major sources of IL-10 as well as IL-4 (Mizuno et al.,
1994). Pousset et al., 1999 proposed that IL-4 and IL-10 might be active at
different stages of the inflammatory response. Previous research investigated the
effects of these anti-inflammatory cytokines on IL -ip induced IL-6 production by
mouse primary astrocytes and reported that IL-4 and IL-10 differentially regulate
IL-6 levels in activated astrocytes. They further suggested that IL-10 has anti
inflammatory properties while IL-4 represents stimulating effects depending on
the cell type and cytokine environment (Pousset et al., 2000).
IL-10 activates the Jak/stat signaling pathway. It is suggested that IL-10
interferes

with

the

Jak

family

tyrosine

kinases

by

inducing

tyrosine

phosphorylation and activating transcription of latent transcription factors stat3
and S tatl (Finbloom DS, Winestock KD., 1995). In addition, it was also reported
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that IL-10 inhibits N F - k B activation in response to stimuli. This accom plished by
two plausible mechanisms. The first is by inhibiting the activation of I k B kinase,
and the second, by inhibiting N F - kB DNA binding activity (Schottelius et al.,
1999). Furthermore, Pousset et al., 2000 reported that intracellular signaling
pathways such as N F k B and Akt may be connected and downregulated by IL-4
and IL-10. Previous results also suggested that these anti-inflam m atory cytokines
m ay

block the

inflammatory

effects

of IL -ip

through

these

pathways

in

astrocytes.
The anti-inflammatory properties of interleukin-10 need to be further
investigated in light of its known functions of macrophage activation and T cell
cytokine synthesis (M oore et al., 1993). Also, by further investigation of anti
inflammatory

cytokines

and

chemokines,

inflammatory

processes

in

neurodegenerative diseases such as AD can be better understood.

Hypothesis Statem ent
Although IL-10 has been studied as an anti-inflammatory cytokine, its
effects on astrocytes and in particular C 6 glioma cell line, need to be further
investigated.

As

reported

previously,

IL-10

interferes with

N F kB

signaling

pathway (Pousset et al., 2000). Since N F kB signaling pathway as well as p38
can also be activated by IL -ip and T N F -a to induce the release of IL-6, we
hypothesize that : [1] IL-10 inhibits the synergistic induction of IL-6 m ediated by
IL -ip and TN F-a; and [2] IL-10 may also interfere with IL-6 transcription induced
by T N F -a and IL -ip .
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C H A P TE R 2

M A TE R IA LS A N D M E T H O D S
Chemicals, Reagents and Equipment
y-Aminobutyric

acid

(GABA),

glycine,

sodium

chloride

(NaC I),

potassium

chloride, 4-(2-hydroxyethyl)-m onosodium salt (H E P E S ), sodium dodecyl sulphate
(SDS),

tris-(hydroxym ethyl)am ino-m ethane

m ethane

hydrochloride,

Tw een-20,

(Tris),

dimethyl

tris-(hydroxymethyl)aminosulfoxide

(D M S G ),

2-

mercaptoethanol (P-M E), and bromophenol blue w ere obtained from SigmaAldrich (St. Louis, M O ) and w ere of the highest grade possible. High molecular
weight poly-D-lysine (PDL) hydrobromide was obtained from BD Biosciences
(Bedford,

MA).

The

prestained

protein ladder w as obtained from

Bio-Rad

(Hercules, CA). Roswell Park Memorial institute (R P M I)-1 6 4 0 , PSN antibiotic
mix,

trypsin-ethylenediaminetetraacetic

acid

(E D TA ),

heat-inactivated

fetal

bovine serum (FBS), phosphate buffer saline (PBS pH 7.2), R N easy M INi Kit,
quantiTec Reverse Transcription
Q IA G EN,

Kit and

Q Iashredder w ere obtained from

USA. Trypan blue was obtained from Invitrogen (Carlsbad, CA).

Methanol was obtained from E M D Chemicals (Gibbstown, NJ). Bovine serum
albumin

(BSA)

w as

obtained

from

Gemini

Bioproducts

(Woodland,

CA).

Recombinant rat IL -ip , T N F -a , IL-10, IL-4 and anti rat IL-6 antibodies were
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obtained from PeproTech Inc. (Rocky Hill, NJ). Rabbit anti-rat I kB-q , I kB-P,
phosphorylated p38 (T 1 80/Y 1 82), total p38, rabbit anti-rat IL-6 antibody, p-Actin
and the biotinylated protein ladder was obtained from Cell Signaling (Danvers,
MA).

Goat anti-rabbit and

goat anti-mouse

horseradish

peroxidase

(H R P )

conjugated secondary antibodies w ere obtained from KPL (Gaithersdurg, MD).
The rat C 6 Gliom a cell lines w ere obtained from the Am erican Tissue Type
culture

Collection

immunosorbent

(Rockville,

assay

MD).

(ELISA )

Rat

kits,

IL-6

sandwich

M -P E R ® ,

enzyme-linked

precasted

12%

SDS-

polyacrylamide gel electrophoresis (PA G E) gels, protease and phosphatase
inhibitor cocktails, and the m icroBCA® [rotein assay kit w ere all obrained from
Pierce

Biotechnology

(Rockford,

IL).

Hoefer

SE

260

minivertical

gel

electrophoresis unit, E P S 2A 200 Power supply, Hoefer T E 22 tank transfer unit,
MultiTemp III thermostatic circulator. Enhanced Chem ilm inescence (ECL)-Plus®
detection reagent was obtained from Am ersham (Piscataway, NJ). Schleicher &
Schuell Optitran® brand supported 0.45 um nitrocellulose m em branes were
obtained from ISC Bioexpress (Kaysville, LIT). Rabbit anti-rat IL-6 antibody was
purchased from

Cell Sciences (Canton,

MA). All small molecule inhibitors

dissolved in sterile solvent, aliquoted and stored at -2 0 °C until use. The final
concentrations of D M S O never exceeded 0.1% of the final solution.

C 6 Glioma Cell Culture
Rat C6 glioma cells w ere maintained in continuous culture in a humidified
atmosphere containing 95% air and 5% C O 2 in complete medium (R P M I-1 6 4 0 /
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phenol red, medium containing 10% heat-inactivated FBS, 25m M H E PE S pH
7.4, and PSN antibiotic mix). Cells were grown either in 25 cm^ or 75 cm^ area
flasks. After 3-4 days in culture, cells were removed from the tissue culture flasks
v\/ith 2 mL (for the 25 cm^ area flask) or 6 mL (for 75 cm^ area flask) of 0.25%
trypsin/ 0.05% E D TA in Hanks-buffered salt solution. Trypsin was inactivated
upon the addition of 8-24 ml of complete medium, cells were centrifuged,
pelleted, supernatant removed, and the pelleted cells resuspended in complete
medium. Cell suspension densities and cellular viability were determined via
trypan blue exclusion. The cells w ere then placed (passed) back into continuous
culture (1.25x10® cells/25 cm^-area flask, BD Falcon) or w ere seeded into tissue
culture plastic-ware

at the plating

densities

noted for experiments.

In all

experiments presented, C6 glioma cells w ere used between passages 5-35.

Cytokine Quantification via ELISA
Rat C6 cells w ere plated (0 .1 2 5 x 1 0®/well) on a 96-well plate using Poly-D-Lysine
(PDL) in complete medium and allowed to incubate 24 h to ensure attachment.
For the experiment, cells w ere washed twice with 2mll serum -free RPMI 1640
and incubated serum or serum -free R P M I-1640 in the absence or presence of
agents for the times and doses indicated for the experiments. IL-6 release was
then assayed via rat IL-6

ELISA (Pierce Biotechnology) according to the

m anufacturers’ instructions.
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Colletion of Cellular Protein Lysates
Rat C6 glioma cells w ere plated (3.0x10®/dish) on PDL-coated 35x10mm dishes
in complete medium and allowed 24 h to attach. Following the attachment period,
the cells were washed twice with 2ml serum-free R P M I-1 6 4 0 and incubated in
serum or serum -free R P M I-1 6 4 0 in the absence or presence of stimulating
agents for the times and concentrations. After treatm ents cells were washed
twice in 2ml ice cold PBS and scraped in 200pL of M -P E R ® (Pierce), containing
both phosphatase and protease inhibitors (each from Pierce). Protein- containing
solutions w ere kept on ice and vortexed in 10 min intervals for a total time of 30
min on ice. Lysates w ere then centrifuged at 14,000 x g for 10 min at 4°C , and
175pL

of

the

supernatant

was

recovered.

Protein

concentrations

were

determined with Micro-BCA protein assay kit (Pierce) using BSA as a standard.
Protein lysates w ere diluted by 20% using a 2X S D S -P A G E loading buffer (10%
w/v SDS, 2% v/v glycerol, 0.1% w/v bromophenol blue, 0.5M Tris pH 6.8, and 5%
v/v P-M E), and boiled for 2 min. Protein lysates were subsequently separated by
S D S -P A G E W estern blot analysis or at -80°C for future analysis.

R N A Extraction and Semi-Quantitative R T -P C R Analysis
Rat 0 6 glioma cells w ere plated (3.0 X 10®/dish) on PDL-coated 35 X 10mm
dishes

in complete

medium,

and

allowed

24

h to

attach.

Following the

attachment period, the cells w ere washed twice with 2 ml serum -free R P M I-1640
and incubated in 10% FBS R P M I-1 6 4 0 in the presence or absence of stimulating
agents for the times and doses indicated for the experim ents. After treatments
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cells were washed twice in 2ml ice cold PBS. Total R N A w as then extracted
using Q IA G E N R N easy M INI Kit purification system.
To detect the presence of m R N A encoding IL-6 and

P-Actin, sem i-

quantitative R T -P C R analysis were performed as described by Elsawa et al.,
2004 and Bost et al., 1995. O ne pg of the total R N A was reverse transcribed
using Q uantiTec Reverse Transcription Kit (Q IA G E N ) and apportion of the total
cDNA

was

amplified

using

94°C

dénaturation,

55°C

annealing

and

7 2°C

extension tem peratures, for 30 cycles with the first four cycles having extended
times. Positive and negative strand primers used for the amplification of each
m RN A species w ere obtained from Q IA G E N , USA. Specific sequences were not
supplied

because

of

company

propriety

rules.

Amplified

products

w ere

electrophoresed on 0.5pg/m l ethidium bromide stained gels and visualized under
U V illumination. Analysis of cD N A samples were corrected for expression of PActin.

S D S -P A G E W estern Blot Analysis
Protein lysates w ere separated on a S D S -P A G E gel. Poly-acrylam ide gles w ere
purchased precasted (Pierce). The gels were subsequently transferred to a
Hoffer (0.1 M H E P E S , 0.1 M Tris, 0.1% w/v S D S ) running buffer. Equal amounts
of protein w ere loaded into each lane of the precast gel. Biotinylated and
prestained protein ladders w ere also loaded onto the stacking gel to determ ine
the molecular weight mobility and transfer efficiency, respectively. The proteins
were electrophoretically separated at 4°C , using a constant voltage of 100V.
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Following electrophoresis, the proteins were transferred (H oefer T E 2 2 Mighty
Small TransPhor Tank, Am ersham ) to 0.45 pm nitrocellulose m em branes at 4°C ,
using constant am perage of 360 mA for 90 min in W estern Transfer buffer (25
mM Tris, 192 m M Glycine, and 20% v/v methanol, note: pH was not adjusted).
Following the transfer period, protein-containing m em branes w ere washed once
for 5 min in tris-buffered saline containing tween (TBST: 50m M Tris pH 7.4, 150
mM NaCI, and 0.1 % v/v Tw een-20) for 5 minutes. After the washing period the
m em branes

w ere

blocked

with

TBST

containing

5%

nonfat

milk

(Nestle

Carnation) for 1 hour, then washed three times in 5 min intervals in TB ST. The
m em brane w as incubated 12 h with primary antibodies at 4°C . After the antibody
incubation period, the antibody solution was removed and the m em branes
washed in T B S T three times for 5 min intervals. M em branes w ere then incubated
with a secondary antibody conjugated to a horseradish peroxidase (H R P ) and
anti-biotin. Both secondary and anti-biotin antibodies w ere diluted using the
m anufacturers’

recommendation,

of

1:5000

and

1:1000,

respectively.

All

antibodies w ere diluted in T B S T containing 5% BSA. The incubation period for
secondary antibody and anti-biotin w a s i h and afterwards both w ere removed
and washed in T B S T three times for 5 minute intervals. Proteins were visualized
on the Typhoon multipurpose imager using the EC L-plus® detection reagent
(Amersham).
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Statistical Analysis
Statistical analyses consisted of analysis of variance (ANO VA ), with
significance

confirmed

using the

Bonferroni test for multiple

comparisons

(GraphPad Instat, version 3.0). A P-value of < 0.05 was considered significant.
W here appropriate, data expressed as the mean ± S E M of groups consisting of
three to four observations and each experim ent was performed at lest three
times.
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C H A P TE R 3

RESU LTS
Other inhibitory modulators and their effects on IL-13 signaling
W e investigated the effects of various signaling molecules, both inhibitors and
enhancers of two signaling pathways: NF-kB and p38 MARK. The effects of
serotonin (5-H T) and lipoic acid (LA) on IL-13 mediated phosphorylation of p38
w ere investigated in a W estern format. As suggested in literature, these inhibitory
molecules

are

potent

anti-inflammatory

mediators.

IL-13

successfully

phosphorylates the total p38, but 5-H T was unable to reverse the effects of this
cytokine (Figure 2). Moreover, different concentrations of 5 -H T w ere not able to
reduce the p38 phosphrylation induced by IL-1 3 (Figure 3).

Modulators affecting cAMP
Bu2cAM P increases cAM P and therefore the phosphorylation of p38 however, no
synergistic effect w as observed with IL-13 and Bu 2cAM P co-treatm ents (Figure
2).The effects of cholera toxin (CT), norepinephrine (N E ) and isoprotrenolol (IPT)
were investigated and compared to that of 5-H T by W estern blot format. C T and
NE were postulated to synergise IL-13 mediated phosphorylation of p38. NE acts
through the 3- adrenergic receptor to increase intracellular levels of cAM P but
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showed no synergistic induction in p38 phosphorylation when applied together
with IL-1 p. However, IP T showed decrease in p38 phosphorylation (F ig u re 4).
W e further investigated the effects of IP T on IL -ip signaling. O ur results showed
no further proof of IP T decreasing IL -ip mediated phosphorylation of p38
(Figure 5).

Effects of lipoic acid on IL -ip signaling
W e investigated the effects of LA and its potential in inhibiting the signaling of ILip

and

T N F -a .

We

observed

that

both

IL -ip

and

T N F -a

induced

p38

phosphorylation and I k B- o degradation with no effect on total p38 and k B -p .
Lipoic acid was not able to reverse the activation of either pathway mediated by
IL-1 p or T N F -a (F ig u re 6, 7 )..

Effects of serum vs. serum free medium on IL-6 ELISA assay
W e next investigated the effects of serum (10% FBS, R PM I - 1640) versus serum
free (R PM I - 1640) in ELISA format. Both methods showed good standard curves
with

high

R

values

(results

not shown). A

robust synergistic release

of

extracellular IL-6 due to IL -ip and T N F -a was observed in both experiments
(F ig u re 8 - P anel [A] and [B]). Both GABA and IL-10 w ere able to suppress the
synergistic induction of IL-6, suggesting that they m ay have the sam e mode of
anti-inflammatory

action.

In addition,

serum

conditions showed

suppression of IL-6 induction than serum free (R P M I -
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larger fold

1640) (F ig u re 8,).

Interestingly, serum free samples had more IL-6 in pg/well than 10% FBS R PM I 1640 alone.
Effects of concentration of IL-10 and GABA on extracellular IL-6 release
Having determ ined that serum containing medium allows for better fold induction
suppression of IL-6, w e characterized the dose response effects of IL-10 and
GABA on IL-6 suppression. In serum containing medium, w e showed the highest
concentrations of G ABA and IL-10, 1 mM and 100 ng/ml, respectively, were able
to best suppress the synergistic induction of IL-6 due to IL -ip and T N F -a . W e
also showed that even lower concentrations of GABA (0.2 m M ) and IL-10 (10
ng/ml) induced some suppression of release of IL-6 (Figure 9).

Extended dose response of IL-10 on extracellular IL-6 release
Once w e determined that the IL-10 reverses the synergistic induction of IL-6 due
to IL -ip and T N F -a , w e investigated its effects in an extended dose response.
Groups w ere treated with 1, 5, 10, 25, 50 and 100ng/m l of IL-10. Highest
concentration of IL-10 (100ng/m l) most efficiently suppressed the IL-6 release.
Furthermore, concentrations as low as

1 and

5 ng/ml IL-10

reduced the

synergistic release of IL-6 (Figure 10).

Effects of IL-4 compared to IL-10 and GABA in ability to suppress extracellular
IL-6 release
W e decided to test the test the effects of IL-4, a similar cytokine to IL-10,
believed to have the sam e effects on IL-6 suppression. IL-4 w as able to suppress
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IL -ip and T N F -a synergism in inducing IL-6 release almost the sam e fold as
GABA and IL-10. further, S B 203580, an inhibitor of p38 activity completely wiped
out the signal of IL-6 release, suggesting involvement of p38 M AP kinase in this
pathway (Figure 11).

Effects of serum vs. serum free in W estern format
The effects of serum vs. serum free medium in the ELISA assays suggested that
serum medium was to be our working medium. W e had to standardize this
procedure for our W estern format, so w e investigated the sam e effects in a
W estern blot. Both IL -ip and T N F -a w ere able to induce the phosphorylation of
total p38 and the degradation of k B -a (inhibitor of NF-kB), but not kB -p . W e also
showed synergy of the two cytokines in their ability to induce those two signaling
pathways. IL-10 (100 ng/ml) was unable to reverse the effects from IL -ip and
T N F -a. Also, w e once again showed that serum conditions (10% FBS in RPM I 1640) allowed greater induction of p38 phosphorylation, k B -a degradation, and
cellular accumulation of IL-6 (Figure 12). Furthermore, w e performed separate
experiments involving serum vs. serum free conditions and compared the effects
of GABA and IL-10 on IL-1 P and T N F -a signaling (Figures 13,14).

Effects of different concentration of IL -ip on p38 phosphorylation
After

having

determined

that

serum

rich

conditions

are

optimal

for our

experiments, w e investigated the role of IL-10 on IL -ip and T N F -a signaling. W e
further

explored

the

idea

that

IL-10
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may

affect

IL -ip

signaling

at

low

concentrations for this pro-inflammatory cytokine. W e found that IL-13 was able
to stimulate phosphorylation of p38 even at concentrations as low as 10 ng/ml. In
addition, IL-10 did not inhibit the p38 activation due to low concentrations of ILip . Furthermore, IL-10 did not induce any activation of p38 when administered
alone (F ig u re 15).

Effects of different concentrations T N F -a on p38 phosphorylation
Since we determined that IL-10 had no effect on IL -ip induced p38 activation, we
decided to test another hypothesis that IL-10 may affect the T N F -a mediated
phosphorylation of p38. W e found that T N F -a, like IL -ip induces activation of p38
even at low concentrations of 10 ng/ml. W e observed a dose response of T N F -a
on p38 activation. IL-10 did not reverse the effects of T N F -a on p38 at any
concentrations of the co-treatments (F ig u re 16).

Effects of different concentration of IL -ip on I kB degradation
W e further investigated the effects of IL-10 on IL -ip m ediated degradation of I kBa in N F - kB signaling. As expected, IL-1 p was able to initiate degradation of k B -a ,
inhibitor of N F - kB, with no change in kB -p . However, IL-10 w as not able to
reverse k B -a degradation even at lowest concentrations of IL -ip of 10 ng/ml.
Moreover, IL-10 alone had no effect on k B -a degradation (F ig u re 17).
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Dose response effects of T N F -a on degradation of k B -a : role of IL-10
W e also investigated the hypothesis that IL-10 m ay have a role on T N F -a
mediated

N F - k B signaling. T N F -a

activated the degradation of the

N F - kB

inhibitor k B -a at 10 ng/ml. W e also observed a dose response of T N F -a in N F 
kB

signaling. Som e decrease in the intensity of the bands was observed when

co-treatments with IL-10 w ere administered. This suggested that IL-10 may have
a modest effect on T N F -a mediated k B -a degradation. IL-10 had no effect on
degradation of k B -a , as shown in previous experiments and neither of these
cytokines showed any change in kB -P , as expected (F ig u re 18).

Effects of IL-10 and IL-4 on IL -ip and T N F -a mediated synergistic p38 activation
and k B -a degradation
W e previously showed in an ELISA format that IL-10 and IL-4 inhibited the
cytokine synergistic release of IL-6. W e decided to further investigate the
hypothesis that these two anti-inflammatory cytokines may decrease intracellular
levels of IL-6 by reversing p38 phosphorylation and k B -a degradation induced by
T N F -a and IL-1 p. As expected, both cytokines, T N F -a and IL -ip , induced p38
phosphorylation and k B -a degradation in a synergistic fashion. IL-10 and 11-4,
however, did not have any effect on these two signaling pathways. There was no
change in k B -a or total p38, as shown before by any of the cytokines (F ig u re
19). In addition, w e also included the effects in JN K phosphorylation w here IL-10
was able to reduce the phosphorylation of JNK mediated by T N F -a and IL -ip .
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Tim e course of T N F -a and IL-1P synergism on IL-6 release
W e decided to investigate the optimal time response for IL-6 induced by T N F -a
and IL-1 p. Interestingly, both cytokines induced IL-6 intracellular levels at their
optimal

concentrations,

100

ng/ml

and

50

ng/ml,

respectively.

Moreover,

differences in time course w ere not observed for any of the treatm ent groups and
IL-6 remained unchanged for 1 h to 6 h (Figure 20).

Effects of IL-10 and GABA on T N F -a and IL -ip signaling
W e investigated the effects of longer intervals of T N F -a and IL -ip signaling (in, 4
h and 6 h). Previously, w e found that even at an extended time response both
cytokines are able to stimulate the degradation of k B -a and release of IL-6
(results not shown). On the contrary, IL-10 and GABA, did not reverse the effects
of inflammatory cytokines on NF-kB signaling or change intracellular IL-6.
Moreover, levels of p-actin and k B -P remained unchanged. In addition, levels of
IL-6 stimulation remained the sam e at both 4 h and 6 h treatm ent groups (Figure

21 ).

Effects of T N F -a and IL -ip on short time treatm ent in accumulation of
intracellular IL-6
Previous results suggested that accumulation of intracellular IL-6 remained
unchanged in treatments from 1 h to 6 h. W e first expanded the time response
from 2, 4 to 24 hours (Figure 22). Surprisingly, IL-6 content remained the sam e
throughout the time response. Total p38, k B -p and P-actin remained also
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unchanged as expected. The phosphrylation of p38 however, showed stimulation
by both T N F -a and IL -ip , and interestingly, was decreased by IL-10 at 2 and 4 h
treatment. W e decided to constrict the time frame of measuring IL-6 at 15 min
and 30 min. W e also included the effects of GABA, IL-4 and IL-10 on T N F -a and
IL -ip signaling (Figure 23). All anti-inflammatory modulators showed decrease in
p38 phosphorylation after stimulation with T N F -a and IL -ip at 30 min. No effect
was observed at 15 minute treatments and no change w as observed in IL-6
content throughout. Total p38, k B -p or p-actin w ere not altered as expected.

Synergistic transcriptional activation of IL-6 mediated by T N F -a and IL -ip .
Effects of IL-10 and GABA
W e then proceeded to investigate the transcriptional activation of IL-6 mRNA.
Interestingly,

T N F -a

and

IL -ip

are

able

to

synergistically

stimulate

the

transcription of IL-6. G ABA and IL-10, however, w ere not able to reverse this
synergistic response. W e also tested S B 203580 compound, known to interfere
and inhibit p38 activity. In fact, S B 203580 was able to completely suppress IL-6
transcriptional

activation

mediated

by

T N F -a

and

IL -ip ,

suggesting

its

involvement in this signaling pathway (Figure 24).

Effects of IL-10 on JNK M AP kinase activation
Since IL-10 did not interfere with p38 or N F - k B signaling, w e decided to explore
the

possibility of its interference with

JNK

kinase,

another

M AP

kinase.

Surprisingly w e found that IL-10 reversed the phosphorylation of JNK induced by
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T N F -a and IL-1p suggesting a plausible interference point of IL-10 in our
pathway of investigation (Figure 25, 26).
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C H A P TE R 4

D IS C U S S IO N
Synergistic interaction between Interleukin-1 P and catecholamines
After extensive literature review w e decided to study the effects of
catecholamines and other signaling molecules increasing intracellular level of
cAMP on IL -ip signaling pathway. J. Zum walt et al., 1999 previously showed
synergistic release of IL-6 mediated by IL -ip and Bu 2cAMP, cholera toxin,
norepinephrine

and

isoprotenolol.

Our

lab

previously

showed

that

IL -ip

stimulates p38 phosphorylation and k B -a degradation which ultimately leads to
release of IL-6 (data not shown). W e tested the synergistic effects of IL -ip
together with BU2CAMP, cholera toxin, norepinephrine and isoprotenolol on p38
phosphorylation (Figure 4, 5). Optimal treatment times for stimulation of p38 by
IL -ip

was

determ ined

previously

to

be

15

min.

Co-treatments

with

catecholamines w ere not able to increase activation of p38 in a synergistic
manner. W e determ ined that optimal concentrations of Bu 2cAM P (1 m M), CT
(250 ng/ml), N E (100 pM) and IPT (10 pM) as suggested by literature, w ere not
able to increase p38 phosphorylation. This suggests that their synergism in IL-6
release m ay go through a different pathway other than p38 MAPK. Moreover,
catecholamines did not stimulate p38 phosphorylation when administered alone.
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W e also investigated the effects of other inhibitors and modulators such as
Serotonin

(5-H T ) on p38 activation mediated

by IL-1 p.

Previous research

suggested that 5 -H T was able to reverse IL-6 m R N A expression in M C -3 cells
(C. M ahe et al., 2005). Our results concluded that 5 -H T w as not able to inhibit
and reverse the phosphorylation of p38 induced by IL -ip and therefore may not
inhibit IL-6 gene transcription through this pathway (Figure 2, 3).
W e further investigated the effects of lipoic acid on IL -ip stimulated p38
and NF-kB pathways. W e expected that lipoic acid would be a potent inhibitor of
IL -ip mediated activation. However, our results showed that lipoic acid was not
able to reverse the effects of IL-1 p stimulation (Figure 6, 7).

Interleukin-10 inhibition of the synergistic release
of IL-6 by T N F -a and IL-1 p
Our lab has previously established that T N F -a and IL -ip combined induce a
synergistic effect on IL-6 release (Roach et al., in press). Previous research also
introduced the effects of GABA on the inhibition of IL-6 release induced by T N F -a
and IL-1 p. W e investigated the effects of the anti-inflammatory cytokine, IL-10, on
the synergistic release of IL-6 in ELISA format. Pousset et al. (2000) showed that
infalmmatory cytokine IL -ip can induce N F - k B activation in primary mouse
astrocytes. Furthermore, they showed that anti-inflammatory cytokines IL-10 and
IL-4 were

able

to

block the

IL -ip

induced

N F - k B activation. W e

further

investigated this idea and studied the effects of IL-10 on IL -ip and T N F -a
mediated p38 phosphorylation, N F-

kB

activation and release of IL-6 in rat C6
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astrocytes. In order to further understand the fold induction of IL-6 release and its
suppression, w e explored the effects of serum containing medium (10% FBS,
RPM I - 1640) vs. serum free medium (R PM I - 1640). Our results indicated that
serum rich containing medium induced better fold suppression of synergistic
induction of IL-6 by GABA and IL-10 (Figure 8). Synergistic extracellular IL-6
release was best suppressed at optimal concentrations for G ABA (1 m M) and IL10 (100 ng/ml) in serum. W e also observed that serum free treatments induced
larger release of IL-6 but we achieved greater fold suppression when treatments
w ere m ade in serum rich medium. W e were also able to generate a dose
response of G ABA and IL-10 in ELISA format showing dose dependence of
inhibitory modulators over inflammatory cytokines, IL -ip and T N F -a (Figure 9).
Lowest doses of G ABA and IL-10, 0.2 mM and 10 ng/ml, respectively, just
slightly suppressed IL -ip and T N F -a synergism. However, highest doses of
G ABA (1 m M ) and IL-10 (100 ng/ml) suppressed IL-6 induction by approximately
50% . In addition, when G ABA and IL-10 w ere administered alone, no change in
IL-6 release was measured.
To determ ine the minimal and maximal effective doses of IL-10 in reducing IL6 in ELISA, w e performed treatments with six different doses ( 1 - 100ng/ml). C o
treatments of IL -ip and T N F -a together with IL-10 inhibited IL-6 release at 100
ng/ml IL-10. Moreover, 1 ng/ml IL-10 of also slightly suppressed IL-6 release

(Figure 10).
Further, w e compared inhibition of IL-6 release by IL-10 and GABA to that of
IL-4 and S B 203 580 in ELISA. As suggested by the literature, IL-4 has anti
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inflammatory properties similar to IL-10 (F. Pousset et al., 200 0). W e expected to
observe IL-4 inhibition of IL-6 similar to that of IL-10. In fact, IL-4 suppressed ILi p and T N F -a synergistic induction of IL-6 similarly to IL-10 and GABA (Figure

11). In addition, S B 203580, a p38 inhibitor, completely reversed the effects of ILip

and T N F - 0

on IL-6 release. Our results show that each of these anti

inflammatory cytokines and inhibitors in the C N S m ay have a similar mode of
action. J. Roach, et al., (2008) suggested that GABA m ay inhibit IL-6 translation
by blocking IL-6 transcript release form the nucleus or by inhibiting translation
directly. With these results w e can prove our first hypothesis that IL-10 inhibits
synergistic induction of IL-6, due to T N F -a and IL -ip . From the data presented,
we decided to investigate further the effects of IL-10 on p38 and NF-kB activation
by W estern.

Effects of Interleukin-10 inhibition on IL -ip and T N F -a m ediated induction of
IL-6
Since accelerated

effect of p38

phosphorylation

and

NF-kB activation,

induced by IL -ip and T N F -a may be the cause for synergistic induction of IL-6 as
shown in our ELISA data, w e needed to investigate IL-10 activation of these two
pathways. First, w e had to determine our optimal working conditions in serum
rich or serum free medium. Results indicated that synergistic activation of p38
and NF-kB was better expressed in serum containing medium (Figure 12). W e
showed that IL-10 did not consistently reverse p38 phosphorylation or IkB-o
degradation induced by IL -ip and TN F-a. W e observed the expected synergism
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of the two inflammatory cytokines as expected. However, IL-10 100 ng/ml and 15
min co-treatments w as unable to show any effect. In addition, w e observed no
change in total p38, I kB-3, 3-actin, as expected. Moreover, IL -10 did not reduce
intracellular accumulation of IL-6. W e once again confirmed that treatm ent with
100 ng/ml T N F -a and 50 ng/ml IL -ip resulted in IL-6 transcription and synergistic
induction of p38 and N F - kB. However, IL-10 did not interfere with p38 and I kB- o
activation.
W e also demonstrated that G ABA showed little or no difference in the IL -ip or
T N F -a stimulation of p38 and NF-kB in serum free or serum rich m edium (Figure
13, 14). The reason for this difference of G ABA to IL-10 experim ent in serum vs.
serum free conditions m ay be due to the fact of different cell split num ber or other
experimental conditions.
W e also illustrated dose dependence activation of p38 pathw ay by IL -ip .
Lowest

doses

of

IL -ip

at

10

ng/ml

were

just

slightly

able

to

induce

phosphorylation. On the other hand, highest concentrations of 100 ng/ ml of IL -ip
showed a great induction of p38. Moreover, IL-10 w as not able to inhibit IL -ip
activation of p38 at any dose of IL -ip . Maximal concentrations of IL-10 of 100
ng/ml w ere used for co-treatm ents (Figure 15). W e investigated T N F -a dose
dependence on p38 activation and IL-10 effects. Results show that T N F -a
stimulated p38 phosphorylation at 10 ng/ml as well as at 100 ng/ml. O nce again,
IL-10 did not reverse T N F -a effects on p38 phosphorylation (Figure 16). These
results indicate that IL-10 has no effect on stimulated p38 pathway and therefore
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may not have an effect on intracellular accumulation of IL-6 m essage, which may
be stimulated by acceleration of phosphorylation of p38.
The activation of N F - kB on IL-6 accumulation was also studied. Dose
dependence of both IL -ip and T N F -a was observed to activate I k B-o degradation
with no change in k B -p . In either scenario, IL-10 did not reverse IL -ip or T N F -a
stimulated degradation of I kB- o (F ig u re 1 7 ,1 8 ).
Our ELIS A data shown before suggested that IL-10 inhibits synergistic
release of IL-6 mediated

by IL I-P

and T N F -a .

Therefore, w e decided to

investigate further this response by W estern. N F - k B and p38 activation was
stimulated synergistically by IL I-P and T N F -a at maximal concentrations of 50
ng/ml and 100 ng/ml, respectively. Both anti-inflammatory cytokines, IL-10 and
IL-4 had no effect on I kB- o degradation or phosphorylation of p38 (F ig u re 19). It
was able to inhibit extracellular release of IL-6 induced by IL I-p and T N F -a but
could not influence two of the main pathways involved in IL I-p and T N F -a
signaling.
W e further decided to m easure the IL-6 cellular content when stimulated with
IL I-P and T N F -a and observe any possible effects of IL-10. First, w e wanted to
observe the time dependence of IL-6 stimulation m ediated synergistically by IL1P and TN F -a. F ig u re 20 represents the IL-6 synergistic accumulation by IL I-p
and T N F -a . Interestingly, we observe the same am ount of IL-6 after stimulation of
1 , 2 , 4 and 6 h. Cellular IL-6 remained the sam e throughout the time treatment
and suggested no dependence on time. W e further observed the effects of GABA
and IL-10 on cellular IL-6 content stimulated by IL I-p and T N F -a . Neither GABA
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nor IL-10 was able to reverse IL-6 accumulation at 4 and 6 hours. Furthermore,
we see that both IL -ip and T N F -a induced k B -a degradation, although very
slightly. No change was observed in k B -P or P-actin, as expected (Figure 21).
Since no difference in IL-6 stimulation was observed with 6 h of stimulation with
cytokines, we decided to design an experiment w here IL-6 accumulation was
observed after overnight treatm ent with inflammatory cytokines. Again, we
observed no change in IL-6 content even after 24 h. The inhibitor k B -a was
slightly degraded even after extended times.
remained

unchanged as expected.

k B -P ,

Interestingly,

P-actin and total p38

IL -ip

and T N F -a

induced

phosphorylation in p38 at all time points. Moreover, IL-10 slightly reversed this
effect at 2 and 4 hours compared to GABA (Figure 22). W e therefore decided to
reduce the time fram e for cytokine stimulation. C 6 cells were stimulated for 15
and 30 min with IL -ip
SB 203580

and T N F -a and effects of GABA,

IL-10, IL-4 and

w ere observed. Intracellular IL-6, p-actin and p38 remained the

same. However, phosphorylation of p38 was apparently reversed at 30 min by
GABA, IL-10, IL-4 and S B 203580 compared to 15 minutes treatments (Figure

23). W e w ere not able to deduce with complete accuracy the optimal time frame
for maximal p38 inhibition by IL-10 or any other anti-inflammatory cytokine. There
are many variables in the experiments including cell split number or time of
treatm ent when cells are most responsive.
Finally, w e investigated the effects of IL-10 on IL-6 transcription. W e observed
synergistic activation of IL-6 transcription induced by IL -ip and T N F -a . IL-10 had
no effect and was not able to reverse the stimulation and neither could GABA.
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SB 203580 was a positive control and inhibited IL-6 transcription after stimulation
with inflammatory cytokines (F ig u re 24). In addition, w e decided to test another
M AP kinase and its involvement in our pathway of investigation, c-Jun-N-terminal
kinase (JNK). W e found that when phosphorylation of JNK is stimulated either
with T N F -a or IL -ip , IL-10 reduced pJNK (Fig ures 25, 26). This suggests that
inhibition of extracellular IL-6 release may be through a mechanism involving a
MAP kinase. Results in this thesis and the research performed led us to propose
a plausible point of inhibition by IL-10, represented by F ig u re 27.
These results suggested that IL-10 m ay be interfering at a post translational
level with IL-6 transcript. There are two plausible locations w here IL-10 can
inhibit or prevent IL-6 from leaving the cell. O ne potential model for IL-10
inhibition of IL-6 translation may be through interfering with the ribosomal
assembly and thus reducing the amount of mature IL-6 transcript. Another model
may be similar to the mode of action of brefeldin - A (BFA), a drug that disrupts
the Golgi apparatus and secretory mechanism. In m am m als the target of BFA is
the G T P /G D P

exchange factor required for A R F

(ADP-ribosylation factor)

binding (Helm s and Rothman, 1992;). BFA changes the structure of Golgi
apparatus and block the transport of secretory proteins from the endoplasmic
reticulum (ER ) to the Golgi (Klausner et al., 1992). Therefore, IL-10 may be
preventing glycosylation and formation of mature IL-6 from leaving the cell by
interfering with the Golgi apparatus.
In summary, our results presented in this thesis show the synergistic effect of
IL -ip and T N F -a on the release of extracellular IL-6. W e also showed that both of
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these cytokines are able to stimulate and activate p38 and N F - k B signaling.
Moreover, IL-10 m ay be involved in post-translational mechanism to prevent IL-6
release based on the following: [1] IL-10 did not prevent the activation of p38 or
N F - k B, [2] IL-10 did not reduce transcription of IL-6 [3] IL-10 showed no change
in intracellular IL-6 levels after stimulation with IL -ip and T N F -a [4] IL-10 reduced
phosphorylation of JNK, induced by T N F -a

and IL -ip , suggesting a possible

mechanism involving M AP kinase in inhibiting IL-6 release. IL-10 mechanism of
action is very similar to that GABA, another inhibitory neurotransmitter in the
C N S which may suggest a whole new class of inhibitory modulators interfering at
post-translational level.
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Figure 1: Schem atic representation of p38 and N F - k B signaling induced by IL-1P
and T N F -a and possible IL-10 interference point.
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IL - l(5 0 n g /in l)

5 -H T (lu M )

Bu2cA M P (Im M )

S B ( lO u M )

pp38

p38

Figure 2: Effects of srotonin (5-H T) on IL -ip signaling. Rat C 6 cells were plated
(3.0 X 10® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells were pretreated
with lu M of 5 -H T and Im M of Bu2cAM P for 1 hour and co-treated with lu M of 5HT, Im M of Bu2cAM P and IL -ip (50ng/m l) for 15 minutes. Post stimulation
cellular protein was extracted and 25 pg of the total protein w ere subsequently
separated via S D S -P A G E followed by W estern analysis for total p38 and
phosphorylated p38 protein (1:1000 for all). The data are represented as the
observations obtained from a single experiment.

44

IL-l(50ng/m l)

S -H T (lu M )

5 -H T (SOOnM)

5-H T (lOOnM)

pp38
p38

Figure 3; Effects of concentration of 5-H T on IL -ip signaling. Rat C 6 ceils w ere
plated (3.0 X10® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells w ere
pretreated with lOOnM, 500nm M and Ip M of 5-H T for 1 hour and co-treated with
lOOnM, 500nm M and Ip M of 5-H T and IL -ip (50ng/m l) for 15 minutes. Post
stimulation cellular protein was extracted and 25 pg of the total protein w ere
subsequently separated via S D S -P A G E followed by W estern analysis for total
p38 and phosphorylated p38 protein (1:1000 for all). The data are represented as
the observations obtained from a single experiment.
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IL-l(50ng/ml)

S -H T (lu M )

N E (lO O uM )

CT (250ng/ml)

IPT(10uM)
■■I

pp38

p38

Figure
4;
Effects
of other
inhibitors/modulators
on
IL-13
mediated
phosphorylation of p38. Rat C 6 cells w ere plated (3.0 X10® cells/dish in a PDLcoated 35 X 10 mm-dishes). Cells were pretreated with Ip M 5-HT, lOOpM
NE,250ng/m l Cholera Toxin and lO pM IPT for 1 hour and co-treated with Ip M 5HT, lOOpM NE, 250ng/m l Cholera Toxin, lOpM IPT and IL -ip (50ng/m l) for 15
minutes. Post stimulation cellular protein was extracted and 25 pg of the total
protein w ere subsequently separated via S D S -P A G E followed by W estern
analysis for total p38 and phosphorylated p38 protein (1:1000 for all). The data
are represented as the observations obtained from a single experiment.
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IL -l(50n g/m l)

I P T ( lO O u M )

IP T (lO u M )

IPT ( lu M )

Figure 5: Concentration response of IPT on IL -ip m ediated p38 signaling
pathway. Rat C 6 cells w ere plated (3.0 X10® cells/dish in a PDL-coated 35 X 10
mm-dishes). Cells w ere pretreated with Ip M , lO pM and lOOpM IPT for 1 hour
and co-treated with Ip M , lO pM and lOOpM IPT and IL -ip (50ng/m l) for 15
minutes. Post stimulation cellular protein was extracted and 25 pg of the total
protein were subsequently separated via S D S -P A G E followed by W estern
analysis for total p38 and phosphorylated p38 protein (1:1000 for all). The data
are represented as the observations obtained from a single experiment.
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IL-1 (50 n g /m l)

0.4% EtOH
LA 1 mM
0.2% EtO H
LA 0.5 m M

Figure 6: Lipoic acid as an inhibitor of IL-1 mediated p38 pathway. Rat C6 cells
w ere plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells w ere
pretreated with 0.5m M and Im M lipoic acid for 1 hour and co-treated with 0.5m M
and Im M lipoic acid and IL-13 (50ng/m l) for 15 minutes. 0.4% and 0.2% EtOH
control points w ere showed in order to exclude possible interference with cell
death. Post stimulation cellular protein was extracted and 2 5 pg of the total
protein w ere subsequently separated via S D S -P A G E followed by W estern
analysis for total p38 and phosphorylated p38 protein (1:1000 for all). The data
are represented as the observations obtained from a single experiment.
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0 .4 “/„ EtOH
TNF (100ng/m l) 0.4%
LA 1 mM
0.2% EtOH
TNF (100ng/m l) 0.2%
LA 0.5 mM

I kB-q

I kB-P

Figure 7: Lipoic acid as an inhibitor of T N F -a mediated N F - k B pathway. Rat C6
cells were plated (3.0 X10® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells
w ere pretreated with 0.5m M and Im M lipoic acid for 1 hour and co-treated with
0.5m M and Im M lipoic acid and IL -ip (50ng/m l) for 15 minutes. Post stimulation
cellular protein was extracted and 25 pg of the total protein were subsequently
separated via S D S -P A G E followed by W estern analysis for total p38 and
phosphorylated p38 protein (1:1000 for all). The data are represented as the
observations obtained from a single experiment.

49

Panel [A]

140
120

JL

100

I

80

50

<o

40

X

X
T

X

... 1C.

20

0

-i— —

Tl

G

— I— —

GTI

— I— —

IL-10

— r

ITI

GITI

Panel [B]

350

09
S

300

-

250

-

20 0

-

150

-

100

-

50

-

T

1

1

0

Tl

GTI

IL-10

ITI

GITI

Figure 8: Effects of serum containing medium (Panel [A]) vs. serum free (Panel
[B]) on IL -ip and T N F -a mediated synergistic release of IL-6 in ELISA. Rat C6
cells were plated (125 X 10® cells/well in a PDL-coated 96-well plate) and were
pretreated with inhibitors (Im M GABA, lOOng/ml IL-10) alone for 1h and co
treated with inhibitors alone, 50ng/ml IL -ip and lOOng/ml T N F -a for 24 hours.
Post stimulation, conditioned medium was removed and assayed for IL-6 using
Pierce ELISA according to the m anufacturer’s specifications. T = T N F -a, I = ILip , G = GABA, IL-10 = interleukin 10. The data are represented as m ean ±
s.e.m. of triplicate observations obtained from a single representative
experiment.
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Figure 9: Effects of concentration of GABA and IL-10 on IL -ip a n d T N F -a
mediated synergistic release of IL-6 in ELISA. Rat C 6 cells w ere plated (125 X
10® cells/well in a PDL-coated 96-well plate) and w ere pretreated with inhibitors
(0.1, 0.5 and Im M GABA, 10, 25, 50 and 100ng/ml IL-10) alone for 1h and co
treated with inhibitors alone, 50ng/m l IL -ip and 100ng/ml T N F -a for 24 hours.
Post stimulation, conditioned medium was removed and assayed for IL-6 using
Pierce ELISA according to the m anufacturer’s specifications. T = TN F -a, I = ILip , G = GABA, IL-10 = interleukin 10. The data are represented as m ean ±
s.e.m. of triplicate observations obtained from a single representative
experiment.
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Figure 10: Evaluation of extended dose response of IL-10 on IL -ip a n d T N F -a
mediated synergistic release of IL-6 in ELISA. Rat C6 cells w ere plated (125 X
10® cells/well in a PDL-coated 96-well plate) and were pretreated with inhibitors
(Im M GABA, 1, 2,1 0 ,2 5 ,5 0 and 100ng/ml IL-10) alone for 1h and co-treated with
inhibitors alone, 50ng/ml IL -ip and 100ng/ml T N F -a for 24 hours. Post
stimulation, conditioned medium was removed and assayed for IL-6 using Pierce
ELISA according to the m anufacturer’s specifications. T = T N F -a , I = IL -ip , G =
GABA, IL-10 = interleukin 10. The data are represented as mean ± s.e.m. of
triplicate observations obtained from a single representative experiment.
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Figure 11: Effects of IL-4 vs. IL-10 and GABA on IL-10 on IL -ip an d T N F -a
mediated synergistic release of IL-6 in ELISA. Rat C6 cells w ere plated (125 X
10® cells/well in a PDL-coated 96-well plate) and w ere pretreated with inhibitors
(Im M GABA, 100ng/ml IL-10, 100ng/ml IL-4, lO pM S B 203580) alone for 1h and
co-treated with inhibitors alone, 50ng/ml IL -ip and 100ng/ml T N F -a for 24 hours.
Post stimulation, conditioned medium was removed and assayed for IL-6 using
Pierce ELISA according to the m anufacturer’s specifications. T = TN F -a, I = ILip , G = GABA, IL-10 = interleukin 10, IL-4 = Interleukin 4, SB = SB 203 580. The
data are represented as mean ± s.e.m . of triplicate observations obtained from a
single representative experiment.
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Figure 12: Effects of IL-10 in serum containing medium vs. serum deficient
medium on IL -ip and T N F -a mediated N F - kB degradation and phosphorylation
of p38. Rat C 6 cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10
mm-dishes). Cells w ere pretreated with 100ng/ml IL-10 for 1 hour and co-treated
with 100ng/ml IL-10 and IL -ip (50ng/m l) and T N F -a for 15 minutes. Post
stimulation cellular protein was extracted and 25 pg of the total protein w ere
subsequently separated via S D S -P A G E followed by W estern analysis for total
p38 and phosphorylated p38 protein, k B -a and k B -p . IL-6 and p-actin were
obtained by stripping the m em branes by blocking with non-fat milk overnight and
then probing with primary and secondary antibodies (1:1000 for all). The data are
represented as the observations obtained from a single experiment.
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Figure 13: Effects of G ABA in serum vs. serum deficient medium on
phosphorylation of p38. Rat C 6 cells w ere plated (3.0 X I 0® cells/dish in a PDLcoated 35 X 10 mm-dishes). Cells w ere pretreated with 1 mM G ABA for 1 hour
and co-treated with 1 mM GABA, IL -ip (50ng/m l) and T N F -a (100ng/m l) for 15
minutes. Post stimulation cellular protein was extracted and 25 pg of the total
protein w ere subsequently separated via S D S -P A G E followed by W estern
analysis for total p38 and phosphorylated p38 protein (1:1000 for all). The data
are represented as the observations obtained from a single experiment.
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Figure 14: Effects of GABA in serum vs. serum deficient medium on degradation
of I kB inhibitor of N F - k B. Rat C 6 cells w ere plated (3.0 X I 0® cells/dish in a PDLcoated 35 X 10 mm-dishes). Cells w ere pretreated with 1 mM GABA for 1 hour
and co-treated with 1 mM GABA, IL-13 (50ng/m l) and T N F -a (100ng/m l) for 15
minutes. Post stimulation cellular protein was extracted and 25 pg of the total
protein w ere subsequently separated via S D S -P A G E followed by W estern
analysis for k B -a and kB-|3 protein (1:1000 for all). The data are represented as
the observations obtained from a single experiment.
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Figure 15: Effects of low concentration of IL-13 on p38 signaling pathway. Rat C6
cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells
were pretreated with 100ng/ml IL-10 for 1 hour and co-treated with 100ng/ml IL10 and IL-13 (10 ng/ml, 25ng/m l, 50ng/m l and 100ng/ml) for 15 minutes. Post
stimulation cellular protein w as extracted and 25 pg of the total protein were
subsequently separated via S D S -P A G E followed by W estern analysis for total
p38 and phosphorylated p38 protein (1:1000 for all). The data are represented as
the observations obtained from a single experiment.
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Figure 16: Effects of IL-10 on TN F-a-m ediated phosphorylation p38. Rat C6 cells
were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells w ere
pretreated with 100ng/ml IL-10 for 1 hour and co-treated with 100ng/ml IL-10 and
T N F -a (10 ng/ml, 25ng/ml, 50ng/ml and 100ng/ml) for 15 minutes. Post
stimulation cellular protein was extracted and 25 pg of the total protein were
subsequently separated via S D S -P A G E followed by W estern analysis for total
p38 and phosphorylated p38 protein (1:1000 for all). The data are represented as
the observations obtained from a single experiment.
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Figure 17: Effects of low concentration of IL -ip on N F - k B signaling pathway. Rat
C6 cells w ere plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes).
Cells w ere pretreated with 100ng/ml IL-10 for 1 hour and co-treated with
100ng/ml IL-10 and IL -ip (10 ng/ml, 25ng/ml, 50ng/m l and 100ng/ml) for 15
minutes. Post stimulation cellular protein w as extracted and 25 pg of the total
protein w ere subsequently separated via S D S -P A G E followed by W estern
analysis for I k B- o and I kB-P protein (1:1000 for all). The data are represented as
the observations obtained from a single experiment.
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Figure 18: Effects of low concentration of T N F -a on N F - kB signaling pathway.
Rat C6 cells w ere plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mmdishes). Cells w ere pretreated with 100ng/ml IL-10 for 1 hour and co-treated with
100ng/ml IL-10 and T N F -a (10 ng/ml, 25ng/ml, 50ng/ml and 100ng/ml) for 15
minutes. Post stimulation cellular protein was extracted and 25 pg of the total
protein w ere subsequently separated via S D S -P A G E followed by W estern
analysis for k B -a and kB-|3 protein (1:1000 for all). The data are represented as
the observations obtained from a single experiment.
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Figure 19; Effects of IL-4 vs. IL-10 on IL -ip and T N F -a signaling. Rat C6 cells
w ere plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells were
pretreated with 100ng/ml IL-10 and IL-4 for 1 hour and co-treated with 100ng/ml
IL-10, 100ng/ml IL-4 and T N F -a (100ng/m l) + IL -ip (50ng/m l) for 15 minutes.
Post stimulation cellular protein was extracted and 25 pg of the total protein were
subsequently separated via S D S -P A G E followed by W estern analysis for k B -a ,
I k B-P, total p38 and phosphorylated p38 protein (1:1000 for all). The data are
represented as the observations obtained from a single experiment.
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Figure 20: Tim e dependence of IL-1P and T N F -a mediated synergistic release of
intracellular IL-6 in W estern blot. Rat C 6 cells were plated (3.0 X10® cells/dish in
a PDL-coated 35 X 10 mm-dishes). Cells w ere treated with T N F -a (lOOng/ml)
and IL -ip (50ng/m l) for 1 , 2 , 4 and 6 hours. Post stimulation cellular protein was
extracted and 25 pg of the total protein was subsequently separated via S D S P A G E followed by W estern analysis for IL-6 (Cell Sciences) protein (1:1000 for
all). The data are represented as the observations obtained from a single
experiment.
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Figure 21; Tim e dependence of IL -ip and T N F -a m ediated synergistic release of
intracellular IL-6 of GABA vs. IL-10 in serum rich medium. Rat C6 cells w ere
plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells were
pretreated with lOOng/ml IL-10 and Im M G ABA for 1 hour and co-treated with
lOOng/ml IL-10, Im M G ABA and T N F -a (100ng/m l) + IL -ip (50ng/m l) for 4 and 6
hours. Post stimulation cellular protein was extracted and 25 pg of the total
protein w ere subsequently separated via S D S -P A G E followed by W estern
analysis for k B -a , kB -p , p-Actin and IL-6 protein (1:1000 for all). The data are
represented as the observations obtained from a single experiment.
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Figure 22: Extended time response of IL -ip and T N F -a mediated synergistic
release of intracellular IL-6. Effects of G ABA and IL-10 on p38 and N F - k B
pathways. Rat C 6 cells w ere plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10
mm-dishes). Cells w ere pretreated with 100ng/ml IL-10 and Im M G ABA for 1
hour and co-treated with 100ng/ml IL-10, Im M GABA and T N F -a (100ng/m l) +
IL -ip (50ng/m l) for 2, 4 and 24 hours. Post stimulation cellular protein was
extracted and 25 pg of the total protein w ere subsequently separated via S D S PA G E followed by W estern analysis for p38, pp38, k B -a , kB -P , P-Actin and IL-6
protein (1:1000 for all). The data are represented as the observations obtained
from a single experiment.
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Figure 23: Tim e dependence intracellular IL-6 release. Rat C 6 cells w ere plated
(3.0 X10® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells w ere pretreated
with 100ng/ml IL-10, Im M GABA, 100ng/ml IL-4 and lO pM S B 203 580 for 1 hour
and co-treated with 100ng/ml IL-10, Im M GABA and T N F -a (100ng/m l) + IL -ip
(50ng/m l) for 4 and 6 hours. Post stimulation cellular protein was extracted and
25 pg of the total protein w ere subsequently separated via S D S -P A G E followed
by W estern analysis for k B -a , kB -P , p-Actin and IL-6 protein (1:1000 for all). The
data are represented as the observations obtained from a single experiment.
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Figure 24: Relative expression of IL-6 transcript in cells treated with GABA, IL-10,
T N F -a and IL-1 p. Rat C6 cells w ere plated (3.0 X I 0® cells/dish in a PDL-coated
35 X 10 mm-dishes). Cells w ere pretreated with 10Ong/ml IL-10 and Im M GABA
for 1 hour and co-treated with 10Ong/ml IL-10, Im M G ABA and T N F -a (1 OOng/ml)
+ IL -ip (50ng/m l) for 4 hours. Post stimulation cellular RNA w as extracted and 1
pg of total ENA extract w ere subsequently separated and analyzed via semiquantitative R T -P C R . The data are presented as observations obtained from two
consecutive experiments.
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Figure 25: Effects of IL-10 on TN F-a-m ediated phosphorylation of JNK. Rat C6
cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells
w ere pretreated with 10Ong/ml IL-10 for 1 hour and co-treated with 10Ong/ml IL10 and T N F -a (100, 50, 25, lOng/m l) for 15 min. Post stimulation cellular protein
was extracted and 25 pg of the total protein were subsequently separated via
S D S -P A G E followed by W estern analysis for pJNK and P-Actin (1:1000 for all).
The data are represented as the observations obtained from a single experiment.
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Figure 26: Effects of IL-10 on IL-ip-m ediated phosphorylation of JNK. Rat C6
cells were plated (3.0 X I 0® cells/dish in a PDL-coated 35 X 10 mm-dishes). Cells
w ere pretreated with 10Ong/ml IL-10 for 1 hour and co-treated with 10Ong/ml IL10 and IL -ip (100, 50, 25, lOng/ml) for 15 min. Post stimulation cellular protein
was extracted and 25 pg of the total protein were subsequently separated via
S D S -P A G E followed by W estern analysis for pJNK and total JNK (1:1000 for all).
The data are represented as the observations obtained from a single experiment.
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Figure 27: Postulated mechanism of IL-10 interaction with T N F -a and IL -ip
activation of JNK and p38 M AP kinases.
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